Intellia Therapeutics (NTLA) vs VolitionRX (VNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intellia Therapeutics is the larger company by market cap ($1.83 billion vs $6.4 million), about 288.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | VNRX |
|---|---|---|
| Share price | $13.07 | $0.2113 |
| Market cap | $1.83B | $6.35M |
| 1-day change | +3.73% | -3.69% |
| YTD return | +40.16% | — |
| 1-year return | -48.51% | — |
| 5-year return | -90.34% | — |
| EPS (TTM) | $-3.35 | $-3.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.67M | — |
| Revenue growth (YoY) | +16.92% | — |
| Net income (latest FY) | $-412.69M | — |
| Operating margin | -651.67% | — |
| Net margin | -609.85% | — |
| 52-week high | $28.25 | $10.40 |
| 52-week low | $7.95 | $0.2113 |
| Distance from 52-week high | -53.73% | -97.97% |
| Analyst consensus | buy | none |
| Avg. price target upside | +76.82% | +6345.81% |
| Average volume | 4.26M | 8.47M |
| Shares outstanding | 140.13M | 30.06M |
| Employees | 377 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 288.3 times larger than VolitionRX by market value ($1.83B vs $6.35M).
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About VolitionRX
VNRX stock →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 57 employees
NTLA vs VNRX FAQ
Which is bigger, Intellia Therapeutics or VolitionRX?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.83B compared with $6.35M for VolitionRX (VNRX).
Are Intellia Therapeutics and VolitionRX in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.